MARKET EXPANSION OF REMPLIR WILL BE ACCELERATED AHEAD OF US FDA CLEARANCE EXPECTED IN MARCH/APRIL 2025
Source text: ID:nASX3PzXhn
Further company coverage: OCC.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.